Yannick Auclair, Ph. D.

Scientifique principal

Yannick Auclair est titulaire d'un baccalauréat spécialisé en microbiologie et immunologie ainsi que d'un doctorat en biologie moléculaire obtenu à l'Université de Montréal en 2010.

Ses travaux de recherche doctorale portaient sur l'étude des mécanismes de maintien de la stabilité du génome, des travaux qui ont notamment été récompensés par le Prix de la meilleure thèse de doctorat en 2010 par la Faculté des études supérieures. Appuyé par une bourse du Fonds de recherche du Québec – Santé (FRSQ), M. Auclair a par la suite poursuivi un stage postdoctoral à l'Université McGill (département d'oncologie), où il a pu développer son expertise.

C'est en 2014 que M. Auclair devient professionnel scientifique en santé à l'INESSS. Il occupe présentement le poste de scientifique principal au Bureau - Méthodologies et éthique.

 
DateTitle
08-20-2024Evaluation of intensive behavioural intervention (EIBI) for preschool-age autistic children in Québec
02-13-2024Methodological report in support of the Reflection Guide Supporting Clinical and Organizational Practices in Rehabilitation Services for Young People with Adjustment Problems Aged 10 or Older
12-21-2023Assessment of InterceptTM and MirasolTM Pathogen Reduction Technologies for the Treatment of Labile Blood Products in Quebec
09-18-2023Implantable Medical Device Tracking Methods
06-16-2023Evaluation and Implementation of Digital Health Solutions: A Look at User Participation
05-29-2023Principles and Criteria for Gene Selection for the Molecular Diagnosis of Constitutional Genetic Diseases by Next-Generation Sequencing
09-16-2022Next Generation Sequencing Hereditary Cancer Gene Panels
07-15-2022Hereditary Cardiovascular diseases NGS Panel Evaluation report on the repatriation of an analysis carried out outside of the province of Québec
06-27-2022Molecular profiling of adult solid tumors - Focus PanelTM (IlluminaTM) - 52 somatic biomarkers analysis
02-14-2022Next-generation sequencing (NGS) panels for muscle disease
02-01-2022Detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis by NAAT
01-23-2022Evaluation of Synvisc™ and Synvisc One™ for the management of knee osteoarthritis
01-10-2022Integration of Real-World Data and Evidence into Assessments to Support Decision-Making in the Pharmaceutical Sector
03-16-2021HemlibraTM (emicizumab) - Hemophilia A without inhibitor (re evaluation) - March 2021
02-01-2021Artificial intelligence-assisted diabetic retinopathy tele-screening
01-19-2021Advisability of using molecular tests to clarify the diagnosis of thyroid nodules with indeterminate cytology
01-05-2021Use of the SpaceOAR™ hydrogel rectal spacer during prostate radiotherapy
12-18-2020Xen45 gel implant for micro-invasive glaucoma surgery (migs)
11-24-2020Wound culture: relevance and indications
10-26-2020Continuous glucose monitoring system (Guardian Connect®, Medtronic)
07-31-2020Neonatal screening for nine inborn errors of metabolism
06-29-2020RebinynTM (Nonacog beta pegol) - Coagulation factor IX (Recombinant)
04-08-2020Flash glucose monitoring system (Freestyle libreTM, Abbott) (update april 8, 2020)
02-18-2020The therapeutic value of hyperbaric oxygen (HBO) on children with cerebral palsy
02-17-2020iStent® and iStent inject® trabecular bypass for micro-invasive glaucoma surgery (MIGS)
02-10-2020Continuous glucose monitoring system (Dexcom G6MC Dexcom)
01-27-2020Tomosynthesis and breast cancer: diagnostic evaluation and other uses
01-14-2020VonvendiTM (vonicog alfa) recombinant von willebrand factor – von willebrand disease - Update list - January 2020
12-02-2019HemlibraTM - Update to Québec’s list of blood products, December 2019
09-30-2019AlphanateTM - Update to Québec list of blood products - September 2019
09-03-2019Mise à jour du Répertoire québécois et système de mesure des procédures de biologie médicale - Septembre 2019

Subscribe to our newsletter now

Subscription